U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109271) titled 'CT Body Composition Enhances Survival Risk Stratification' on June 29.
Brief Summary: Gastric carcinoma remains the fifth most common malignancy and the second leading cause of cancer-related mortality worldwide. For patients with locally advanced disease, standard treatment includes radical gastrectomy followed by (neo)adjuvant chemotherapy and immune checkpoint inhibitors. Considerable variability in prognosis persists even within the same the American Joint Committee on Cancer (AJCC) substage, highlighting the importance of host-related factors such as nutritional status, systemic inflammation, and immune competence in shaping sur...